Document is current
Any future updates will be listed below
-
Authors
Oliver, Lindsay D. https://orcid.org/0000-0003-2163-7257
Yu, Ju-Chi
Hawco, Colin
Calarco, Navona https://orcid.org/0000-0002-4391-0472
Tan, Vinh
Moxon-Emre, Iska
Tang, Sunny X. https://orcid.org/0000-0002-4001-8120
Gold, James M.
Foussias, George https://orcid.org/0000-0001-6220-519X
DeRosse, Pamela
Argyelan, Miklos https://orcid.org/0000-0002-7254-1776
Buchanan, Robert W.
Malhotra, Anil K.
Voineskos, Aristotle N. https://orcid.org/0000-0003-0156-0395
,
Carpenter, William T.
Zaranski, Jennifer
Arbach, Eric
August, Sharon
Kochunov, Peter
Kingsley, Peter
Zhou, Xiangzhi
Homan, Philipp
Chavez, Sofia
Remington, Gary
Kwan, Judy
Plagiannakos, Christina
Mason, Mikko
Boczulak, Marzena
Miranda, Dielle
Turner, Jessica
Iacoboni, Marco
Green, Michael
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (1/3R01MH102324–01)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (3/3R01MH102318–01)
- License Information
-
More Information
Article History
Received: 23 January 2025
Revised: 20 January 2026
Accepted: 18 February 2026
First Online: 12 March 2026
Competing interests
: LDO receives grant support from the Brain & Behavior Research Foundation (BBRF). J-CY receives grant support from the Discovery Fund of the Centre for Addiction and Mental Health (CAMH). CH receives grant support from the National Institute of Mental Health (NIMH), Canadian Institutes of Health Research (CIHR), Labatt Family Innovation Fund in Brain Health at the University of Toronto, the Natural Sciences and Engineering Research Council (NSERC), and the CAMH Foundation. NC has no conflict of interest to declare. IM-E was supported by the Labatt Family Network for Research on the Biology of Depression. SXT receives grant support from the NIMH (K23 MH130750, R21 AG082054). SXT also owns equity and serves on the board and as a consultant for North Shore Therapeutics, received research funding and serves as a consultant for Winterlight Labs, is on the advisory board and owns equity for Psyrin, and serves as a consultant for Catholic Charities Neighborhood Services and LB Pharmaceuticals. JMG has no conflict of interest to declare. GF currently receives funding from CIHR, the CAMH Foundation, and the University of Toronto. MA reported no biomedical financial interests or potential conflicts of interest. RWB has served on the Data Safety and Monitoring Boards of Roche, Merck, and Newron, and has served on the Advisory Boards of Merck, Acadia, Karuna, and Neurocrine. AKM receives grant support from the NIMH, Breakthrough Discoveries for thriving with Bipolar Disorder (BD2), and the Wellcome Trust. ANV currently receives funding from the NIMH (1/3R01 MH102324, 1/5R01 MH114970), CIHR, Canada Foundation for Innovation, CAMH Foundation, and University of Toronto.
: All participants signed an informed consent agreement and the protocol was approved by the respective research ethics and institutional review boards at the Centre for Addiction and Mental Health (CAMH), Zucker Hillside Hospital (ZHH), and the Maryland Psychiatric Research Center (MPRC). All research was conducted in accordance with the Declaration of Helsinki.
